Mueller-Brand J - Search Results

1

Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.

Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, Probst A, Gratzl O, Reubi JC, Maecke R, Mueller-Brand J, Merlo A. Schumacher T, et al. Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):486-93. doi: 10.1007/s00259-001-0717-x. Epub 2002 Jan 29. Eur J Nucl Med Mol Imaging. 2002. PMID: 11914886 Clinical Trial.

2

Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas.

Merlo A, Mueller-Brand J, Maecke HR. Merlo A, et al. Acta Neurochir Suppl. 2003;88:83-91. doi: 10.1007/978-3-7091-6090-9_14. Acta Neurochir Suppl. 2003. PMID: 14531566

3

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Waldherr C, et al. J Nucl Med. 2002 May;43(5):610-6. J Nucl Med. 2002. PMID: 11994522 Free article.

4

Kidney failure after treatment with 90Y-DOTATOC.

Schumacher T, Waldherr C, Mueller-Brand J, Maecke H. Schumacher T, et al. Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):435. doi: 10.1007/s00259-001-0720-2. Eur J Nucl Med Mol Imaging. 2002. PMID: 12002721 No abstract available.

5

Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, Arnold M, Mueller-Brand J, Maecke HR, Reubi JC, Merlo A. Kneifel S, et al. Clin Cancer Res. 2006 Jun 15;12(12):3843-50. doi: 10.1158/1078-0432.CCR-05-2820. Clin Cancer Res. 2006. PMID: 16778112

6

90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.

Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. Gerster-Gilliéron K, et al. Among authors: mueller brand j. J Nucl Med. 2015 Nov;56(11):1748-51. doi: 10.2967/jnumed.115.155853. Epub 2015 Aug 20. J Nucl Med. 2015. PMID: 26294303 Free article. Clinical Trial.

7

Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.

Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J. Waldherr C, et al. Nucl Med Commun. 2001 Jun;22(6):673-8. doi: 10.1097/00006231-200106000-00011. Nucl Med Commun. 2001. PMID: 11403179 Clinical Trial.

8

Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.

Merlo A, Jermann E, Hausmann O, Chiquet-Ehrismann R, Probst A, Landolt H, Maecke HR, Mueller-Brand J, Gratzl O. Merlo A, et al. Int J Cancer. 1997 May 29;71(5):810-6. doi: 10.1002/(sici)1097-0215(19970529)71:5<810::aid-ijc19>3.0.co;2-b. Int J Cancer. 1997. PMID: 9180150

9

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.

Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. Otte A, et al. Eur J Nucl Med. 1997 Jul;24(7):792-5. doi: 10.1007/BF00879669. Eur J Nucl Med. 1997. PMID: 9211767

10

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Forrer F, et al. J Nucl Med. 2005 Aug;46(8):1310-6. J Nucl Med. 2005. PMID: 16085587 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters